Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens

Journal of Acquired Immune Deficiency Syndromes

Volumn 29, Issue 3, 2002, Pages 244-253

  Fumaz, Carmina R ^a   Tuldrà, Albert ^a   Ferrer, Ma José ^a   Paredes, Roger ^a   Bonjoch, Anna ^a   Jou, Toni ^a   Negredo, Eugènia ^a   Romeu, Joan ^a   Sirera, Guillem ^a   Tural, Cristina ^a   Clotet, Bonaventura ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Central nervous system disorders; Efavirenz; Emotional status; Protease inhibitors; Quality of life

Indexed keywords

EFAVIRENZ; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CONTROLLED STUDY; DREAMING; EMOTION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; SLEEP DISORDER; TREATMENT OUTCOME; VERTIGO; VIRUS LOAD; VISUAL ANALOG SCALE;

EID: 0036499964     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-200203010-00004     Document Type: Article

References (37)

1. The constitution of the World Health Organization
2. Developing and evaluating cross-cultural instruments from minimum requirements to optimal models
3. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection
4. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
5. Monitoring adherence to HIV-therapy
6. Adherence and its implications for antiretroviral therapy
7. Rethinking nonadherence: Historical perspectives on triple-drug therapy for HIV disease
8. The era of adherence to HIV therapy
9. Adherence and effectiveness of highly active antiretroviral therapy
10. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response
11. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIBV protease inhibitors
12. Calidad de vida y principales preocupaciones asociadas al syndrome de lipodistrofia en pacientes VIH-1+ con supresión viral a largo plazo
13. Quality of life in asymptomatic and symptomatic HIV-infected patients in a trial of ritonavir/saquinavir therapy
14. Quality of life assessments come of age in the era of highly active antiretroviral therapy
15. Efavirenz
16. Efavirenz in the management of HIV infection
17. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV infection in adults
18. Assessment of quality of life, adherence and emotional status in patients treated with efavirenz [late breaker 1204]
19. Potential adverse experiences associated with efavirenz (EFV, SUSTIVA™) in adults
20. Prospective randomized two-arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy
21. EA2: Definitions and standards for expedited reporting E2: Clinical safety, international Conference on Harmonization. Step 5
22. A health status questionnaire using 30 items from the Medical Outcomes Study
23. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: Prospective assessment with implications for enhancing compliance
24. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection
25. Self-efficacy mechanisms in human agency
26. A practical guide to applying the intention-to-treat principle to clinical trials in HIV infection
27. Management of the adverse effects of antiretroviral therapy and medication adherence
28. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions
29. The case for more cautious, patient-focused antiretroviral therapy
30. Hit HIV-1 hard, but only when necessary
31. A risk-benefit assessment of HIV protease inhibitors
32. Impact of PI-sparing HAART regimens on adherence, quality of life and emotional status of HIV-positive patients suffering lipodystrophy
33. Efavirenz tolerability in the real world relation to mental illness, alcohol, and illicit drug use in a large, urban HIV clinic
34. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients
35. Therapeutic drug monitoring (TDM) of nelfinavir and indinavir in treatment-naive patients improves therapeutic outcome after 1 year: Results from Athena
36. Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients